The agreement between Nanologica and AstraZeneca for the evaluation of Nanologica’s pending patented technology applied to AstraZeneca materials has been extended.
The evaluation of the NLAB Silica™ drug delivery platform started at the beginning of 2019. It has now been decided to prolong and expand this collaboration project. The extension of the project is regulated under the same feasibility agreement as signed in January 2019. This extension will further evaluate Nanologica’s platform for the purpose of improving the formulation of an API.
” We are very positive about the extension of the project and are happy to keep working together with AstraZeneca”, says Nanologica’s CEO Andreas Bhagwani.
For further information, please contact:
Andreas Bhagwani, CEO of Nanologica
phone: +46 70 316 17 02 or e-mail: email@example.com
About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size and type of porosity of silica particles. This knowledge is applied within drug delivery and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.